Table 1 Baseline Characteristics of the included cohort.

From: Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study

 

Total Cohort N = 4617

Nonfrail N = 214 (5%)

Prefrail N = 1143 (25%)

Mildly Frail N = 1479 (32%)

Moderately Frail N = 1054 (23%)

Severely Frail N = 727 (16%)

P-value

Age (median,IQR)

75 (70–80)

71 (68–75)

73 (69–78)

75 (70–81)

76 (71–81)

77 (72–83)

<0.01

MM dx Yr

      

0.02

2007

8%

8%

8%

8%

7%

6%

 

2008

10%

11%

12%

10%

9%

6%

 

2009

10%

11%

10%

10%

11%

9%

 

2010

12%

15%

11%

12%

12%

11%

 

2011

12%

8%

11%

12%

13%

13%

 

2012

14%

12%

13%

16%

14%

15%

 

2013

17%

16%

16%

15%

18%

20%

 

2014

18%

20%

18%

17%

16%

19%

 

Sex

Male

52%

57%

57%

52%

50%

46%

<0.01

Race

White

81%

86%

84%

81%

81%

77%

<0.01

Black

13%

6%

10%

13%

14%

16%

<0.01

Other Race

6%

7%

6%

6%

5%

7%

0.35

Medicaid Enrollment

23%

15%

15%

20%

29%

35%

<0.01

MM therapy

PI

68%

65%

68%

67%

68%

70%

0.61

IMID

59%

62%

64%

61%

56%

50%

<0.01

Combination (PI + IMID)

27%

27%

32%

28%

24%

20%

<0.01

  1. IMID Immunomodulatory Drug, PI proteosome inhibitor, OS overall survival, dx diagnosis.